New Delhi: NovaVax Inc.
and Serum Partner Institute of India said on Monday they received an emergency use authorization for their Covid-19 vaccine in Indonesia, making it the world’s first agreement for Novavaks.
Novavaks shares rose by around 11% before the opening bell after the company also said that it has submitted an application for emergency use for vaccines to Canada and the European Medicine Agency.
For Indonesia, shots will be produced by the largest vaccine manufacturer in the world, Serum Institute, and sold under the name of the Indian brand, Covovax.
Novavax said the initial delivery to Indonesia is expected to start at this time.
This country is scheduled to receive 20 million doses of protein-based vaccines this year, according to the government.
Penny Lukito, Head of the National Agency for Indonesian Narcotics and Food Control, did not immediately respond to Reuters’s comment requests.
Novavax has so far proposed EUA in various countries, including Britain, Australia, India and the Philippines.
The company, along with Japanese partners Takeda Pharmaceutical Co., said on Friday it was preparing to seek regulatory approval for launch in Japan early next year.
The Novavaks and Serum Institute has committed to jointly provide more than 1.1 billion doses to Covax facilities, led by the World Health Organization.
The vaccine supply will begin this year after securing an emergency use list from WHO and continuing to 2022.
Novavax has delayed the submission of US agreements by the end of this year, and Politico reported the last month faced production and quality of the problem.
Novavax’s shot was proven to be more than 90% effective, including various Coronavirus variants in large and late US-based clinical trials.